510(k) Report

PMA · Approved

Approved

PD-L1 Ihc 22C3 Pharmdx

P150013PMAApproved Oct 2, 2015179-day reviewClass III

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Agilent Technologies, Inc. · PLS Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1

Approved on Oct 2, 2015 through premarket approval, which rests on the device’s own clinical evidence after a 179-day review.

Decided
Oct 2, 2015
Review
179 days
Class
Class III
Product code
PLS
Recalls
None

PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.

P150013 has 35 supplements since 2016: changes to the approved device, its labelling or its manufacturing, each approved separately.

PMA supplements approved per year

2016: 32017: 42018: 42019: 52020: 42021: 22022: 32023: 22025: 32026: 5
2016high 5 (2019) · low 0 (2024)2026
View FIG. 1 as a table
YearSupplements approved
20163
20174
20184
20195
20204
20212
20223
20232
20253
20265
FIG. 1 — Supplements to P150013, 2016–2026Source: FDA PMA database

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PLS? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

Does it have a predicate?

PMA decisions do not claim a predicate device.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All PLS devices

PLS Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1: FDA decisions, review times, recalls and adverse event reports over 20 years. 2015, this device’s year, is highlighted.

FDA decisions per year · PLS

4in 2025

2015: 12016: 112017: 142018: 102019: 102020: 102021: 72022: 82023: 82024: 42025: 42026 (partial year): 6
2007high 14 (2017) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PLS

Too few PLS 510(k)s in any year since 2007 to give a median.

Recalls per year · PLS

1in 2022

2022: 1
2007high 1 (2022) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · PLS

27in 2023

2017: 22020: 12021: 32022: 22023: 27
2007high 27 (2023) · low 0 (2007)2025

MAUDE reports naming product code PLS, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20151—00
201611—00
201714—02
201810—00
201910—00
202010—01
20217—03
20228—12
20238—027
20244—00
20254—00
20266—0—
Cite this page

510(k) Report. “P150013: PD-L1 Ihc 22C3 Pharmdx.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/P150013

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Page last updated Nov 3, 2026